Breast Cancer - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Breast Cancer > What Your Doctor is Reading About Breast Cancer > Clinical Trials

Clinical Trials

1. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.

Author: Liu MC; Demetri GD; Berry DA; Norton L; Broadwater G; Robert NJ; Duggan D; Hayes DF; Henderson IC; Lyss A; Hopkins J; Kaufman PA; Marcom PK; Younger J; Lin N; Tkaczuk K; Winer EP; Hudis CA;
Institution: Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007-2198, USA. liumc@georgetown.edu
Journal: Cancer Treat Rev. 2008 May;34(3):223-30. Epub 2008 Jan 30.
Abstract URL: Click here to view abstract

2. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.

Author: Nuzzo F; Morabito A; De Maio E; Di Rella F; Gravina A; Labonia V; Landi G; Pacilio C; Piccirillo MC; Rossi E; D'Aiuto G; Thomas R; Gori S; Colozza M; De Placido S; Lauria R; Signoriello G; Gallo C; Perrone F; de Matteis A;
Institution: National Cancer Institute, Naples, Italy.
Journal: Crit Rev Oncol Hematol. 2008 May;66(2):171-80. Epub 2007 Dec 21.
Abstract URL: Click here to view abstract

3. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.

Author: Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D;
Institution: Ohio State University, B402 Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210, USA. Richard.Love@osumc.edu
Journal: J Clin Oncol. 2008 Jan 10;26(2):253-7. Epub 2007 Dec 17.
Abstract URL: Click here to view abstract

4. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

Author: Forbes JF; Cuzick J; Buzdar A; Howell A; Tobias JS; Baum M;
Institution
Journal: Lancet Oncol. 2008 Jan;9(1):45-53.
Abstract URL: Click here to view abstract

5. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

Author: Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Mery E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thurlimann B; Coates AS; Viale G;
Institution: Department of Pathology, Nordsjaellands Hospital, Hilleroed, Denmark. bbr@noh.regionh.dk
Journal: Lancet Oncol. 2008 Jan;9(1):23-8. Epub 2007 Dec 20.
Abstract URL: Click here to view abstract

6. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.

Author: Ganz PA; Hussey MA; Moinpour CM; Unger JM; Hutchins LF; Dakhil SR; Giguere JK; Goodwin JW; Martino S; Albain KS;
Institution: School of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 650 Charles Young Dr South, Room A2-125 CHS, Los Angeles, CA 90095-6900, USA. pganz@ucla.edu
Journal: J Clin Oncol. 2008 Mar 10;26(8):1223-30. Epub 2008 Jan 28.
Abstract URL: Click here to view abstract

7. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial.

Author: Zavagno G; De Salvo GL; Scalco G; Bozza F; Barutta L; Del Bianco P; Renier M; Racano C; Carraro P; Nitti D;
Institution: Clinica Chirurgica II, University of Padova, Italy. giorgio.zavagno@unipd.it
Journal: Ann Surg. 2008 Feb;247(2):207-13.
Abstract URL: Click here to view abstract

8. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.

Author: Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL;
Institution: Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom.
Journal: J Clin Oncol. 2008 Mar 1;26(7):1066-72. Epub 2008 Jan 22.
Abstract URL: Click here to view abstract

9. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.

Author: Schmid P; Kuhnhardt D; Kiewe P; Lehenbauer-Dehm S; Schippinger W; Greil R; Lange W; Preiss J; Niederle N; Brossart P; Freier W; Kummel S; Van de Velde H; Regierer A; Possinger K;
Institution: Medical Oncology, Imperial College London, Charing Cross Hospital, London, UK. p.schmid@imperial.ac.uk
Journal: Ann Oncol. 2008 May;19(5):871-6. Epub 2008 Jan 21.
Abstract URL: Click here to view abstract

10. Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes.

Author: Benekli M; Yildiz R; Uner A; Er O; Yamac D; Alkis N; Coskun U; Camci C; Buyukberber S;
Institution: Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey. mbenekli@gazi.edu.tr
Journal: Oncology. 2007;72(5-6):308-13. Epub 2008 Jan 14.
Abstract URL: Click here to view abstract

11. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.

Author: Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Moller P; Weitzel J; Sun P; Narod SA;
Institution: Lawrence Bloomberg Faculty of Nursing, University of Toronto, Canada.
Journal: J Clin Oncol. 2008 Mar 1;26(7):1093-7. Epub 2008 Jan 14.
Abstract URL: Click here to view abstract

12. Information and decision making: patients' needs and experiences in the course of breast cancer treatment.

Author: Vogel BA; Bengel J; Helmes AW;
Institution: Department of Rehabilitation Psychology and Psychotherapy, University of Freiburg, Germany. vogel@psychologie.uni-freiburg.de
Journal: Patient Educ Couns. 2008 Apr;71(1):79-85. Epub 2008 Jan 8.
Abstract URL: Click here to view abstract

13. Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer.

Author: Saji S; Toi M; Morita S; Iwata H; Ito Y; Ohno S; Kobayashi T; Hozumi Y; Sakamoto J;
Institution: Department of Surgery and Breast Oncology, Division of Clinical Trials and Research, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Journal: Oncology. 2007;72(5-6):330-7. Epub 2008 Jan 12.
Abstract URL: Click here to view abstract

14. The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update).

Author: Holmes DR; Baum M; Joseph D;
Institution: American College of Surgeon, 55 East Erie Street, Chicago, IL 60611-2797, USA. dholmes@usc.edu
Journal: Am J Surg. 2007 Oct;194(4):507-10.
Abstract URL: Click here to view abstract

15. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer.

Author: Benitez PR; Keisch ME; Vicini F; Stolier A; Scroggins T; Walker A; White J; Hedberg P; Hebert M; Arthur D; Zannis V; Quiet C; Streeter O; Silverstein M;
Institution: Department of Surgery, William Beaumont Hospital, 3577 W. 13 Mile Rd, Suite 201, Beaumont Cancer Center, Royal Oak, MI 48073, USA. pbenitez@beaumont.edu
Journal: Am J Surg. 2007 Oct;194(4):456-62.
Abstract URL: Click here to view abstract

16. Survival in breast cancer after nipple-sparing subcutaneous mastectomy and immediate reconstruction with implants: a prospective trial with 13 years median follow-up in 216 patients.

Author: Benediktsson KP; Perbeck L;
Institution: Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Solna, 171 76 Stockholm, Sweden. krispetben@hotmail.com
Journal: Eur J Surg Oncol. 2008 Feb;34(2):143-8. Epub 2007 Aug 20.
Abstract URL: Click here to view abstract

17. Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial.

Author: Spiegel D; Butler LD; Giese-Davis J; Koopman C; Miller E; DiMiceli S; Classen CC; Fobair P; Carlson RW; Kraemer HC;
Institution: Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305-5718, USA. dspiegel@stanford.edu
Journal: Cancer. 2007 Sep 1;110(5):1130-8.
Abstract URL: Click here to view abstract

18. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.

Author: Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S;
Institution: Department of Surgery, Breast Oncology Group, Osaka National Hospital, 2-1-14, Honenzaka, Chuou-ku, Osaka city, Osaka 540-0006, Japan. nmasuda@alpha.ocn.ne.jp
Journal: Cancer Chemother Pharmacol. 2008 May;61(6):989-95. Epub 2007 Jul 20.
Abstract URL: Click here to view abstract

19. Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND.

Author: Goyal A; Newcombe RG; Chhabra A; Mansel RE;
Institution: Department of Surgery, School of Medicine, Cardiff University, Cardiff, United Kingdom. goyala@cf.ac.uk
Journal: Ann Surg Oncol. 2008 Jan;15(1):262-7. Epub 2007 Sep 19.
Abstract URL: Click here to view abstract

20. Multi-institutional experience using the MammoSite radiation therapy system in the treatment of early-stage breast cancer: 2-year results.

Author: Cuttino LW; Keisch M; Jenrette JM; Dragun AE; Prestidge BR; Quiet CA; Vicini FA; Rescigno J; Wazer DE; Kaufman SA; Ramakrishnan VR; Patel R; Arthur DW;
Institution: Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, VA 23298-0058, USA. lcuttino@mcvh-vcu.edu
Journal: Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):107-14. Epub 2007 Nov 26.
Abstract URL: Click here to view abstract

21. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.

Author: Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI;
Institution: National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada. michael.crump@uhn.on.ca
Journal: J Clin Oncol. 2008 Jan 1;26(1):37-43. Epub 2007 Nov 19.
Abstract URL: Click here to view abstract

22. Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation.

Author: Vu T; Ellard S; Speers CH; Taylor SC; de Lemos ML; Hu F; Kuik K; Olivotto IA; Vu T; Ellard S; Speers CH; Taylor SC; de Lemos ML; Hu F; Kuik K; Olivotto IA;
Institution: Provincial Systemic Therapy Program, BC Cancer Agency, Vancouver, British Columbia, Canada.
Journal: Ann Oncol. 2008 Mar;19(3):461-4. Epub 2007 Nov 15.
Abstract URL: Click here to view abstract

23. Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208.

Author: Tokuda Y; Tajima T; Narabayashi M; Takeyama K; Watanabe T; Fukutomi T; Chou T; Sano M; Igarashi T; Sasaki Y; Ogura M; Miura S; Okamoto S; Ogita M; Kasai M; Kobayashi T; Fukuda H; Takashima S; Tobinai K;
Institution: Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. tokuda@is.icc.u-tokai.ac.jp
Journal: Cancer Sci. 2008 Jan;99(1):145-51. Epub 2007 Oct 25.
Abstract URL: Click here to view abstract

24. Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients--longterm follow-up.

Author: Fjosne HE; Jacobsen AB; Lundgren S;
Institution: Breast and Endocrine Unit, Department of Surgery, St. Olavs University Hospital, N-7006 Trondheim, Norway. hans.fjosne@stolav.no
Journal: Eur J Surg Oncol. 2008 Jan;34(1):6-12. Epub 2007 Sep 18.
Abstract URL: Click here to view abstract

25. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial.

Author: Pierce JP; Natarajan L; Caan BJ; Parker BA; Greenberg ER; Flatt SW; Rock CL; Kealey S; Al-Delaimy WK; Bardwell WA; Carlson RW; Emond JA; Faerber S; Gold EB; Hajek RA; Hollenbach K; Jones LA; Karanja N; Madlensky L; Marshall J; Newman VA; Ritenbaugh C; Thomson CA; Wasserman L; Stefanick ML;
Institution: Moores UCSD Cancer Center, University of California, San Diego, La Jolla , CA 92093-0901, USA. jppierce@ucsd.edu
Journal: JAMA. 2007 Jul 18;298(3):289-98.
Abstract URL: Click here to view abstract

26. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.

Author: Papadimitriou CA; Papakostas P; Timotheadou E; Aravantinos G; Bamias A; Fountzilas G;
Institution: Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece.chr_papadim@yahoo.gr
Journal: Cancer Invest. 2008 Jun;26(5):491-8.
Abstract URL: Click here to view abstract

27. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).

Author: Hess D; Koberle D; Thurlimann B; Pagani O; Schonenberger A; Mattmann S; Rochlitz C; Rauch D; Schuller JC; Ballabeni P; Ribi K;
Institution: Department of Internal Medicine, Division of Oncology-Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland. dagmar.hess@kssg.ch
Journal: Oncology. 2007;73(3-4):228-37. Epub 2008 Apr 17.
Abstract URL: Click here to view abstract

28. Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patients.

Author: Kurtz JE; Rousseau F; Meyer N; Delozier T; Serin D; Nabet M; Djafari L; Dufour P;
Institution: Hopitaux Universitaires de Strasbourg, Strasbourg, France.
Journal: Oncology. 2007;73(3-4):210-4. Epub 2008 Apr 17.
Abstract URL: Click here to view abstract

29. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.

Author: Lin NU; Carey LA; Liu MC; Younger J; Come SE; Ewend M; Harris GJ; Bullitt E; Van den Abbeele AD; Henson JW; Li X; Gelman R; Burstein HJ; Kasparian E; Kirsch DG; Crawford A; Hochberg F; Winer EP;
Institution: Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.
Journal: J Clin Oncol. 2008 Apr 20;26(12):1993-9.
Abstract URL: Click here to view abstract

30. Weekly paclitaxel in the adjuvant treatment of breast cancer.

Author: Sparano JA; Wang M; Martino S; Jones V; Perez EA; Saphner T; Wolff AC; Sledge GW Jr; Wood WC; Davidson NE;
Institution: Eastern Cooperative Oncology Group, Philadelphia, USA. jsparano@montefiore.org
Journal: N Engl J Med. 2008 Apr 17;358(16):1663-71.
Abstract URL: Click here to view abstract

31. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.

Author: von Minckwitz G; Kummel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
Institution: German Breast Group, Frankfurt, Germany. minckwitz@germanbreastgroup.de
Journal: J Natl Cancer Inst. 2008 Apr 16;100(8):542-51. Epub 2008 Apr 8.
Abstract URL: Click here to view abstract

32. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.

Author: von Minckwitz G; Kummel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
Institution: German Breast Group, Frankfurt, Germany. minckwitz@germanbreastgroup.de
Journal: J Natl Cancer Inst. 2008 Apr 16;100(8):552-62. Epub 2008 Apr 8.
Abstract URL: Click here to view abstract

33. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.

Author: Greenspan SL; Brufsky A; Lembersky BC; Bhattacharya R; Vujevich KT; Perera S; Sereika SM; Vogel VG;
Institution: Department of Medicine, University of Pittsburgh, 3471 Fifth Ave, Kaufmann Suite 1110, Pittsburgh, PA 15213, USA. greenspans@dom.pitt.edu
Journal: J Clin Oncol. 2008 Jun 1;26(16):2644-52. Epub 2008 Apr 21.
Abstract URL: Click here to view abstract

34. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

Author: Thomas ES;
Institution
Journal: J Clin Oncol. 2008 May 1;26(13):2223.

35. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.

Author: Awada A; Albanell J; Canney PA; Dirix LY; Gil T; Cardoso F; Gascon P; Piccart MJ; Baselga J;
Institution: Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium. ahmad.awada@bordet.be
Journal: Br J Cancer. 2008 May 6;98(9):1500-7. Epub 2008 Apr 29.
Abstract URL: Click here to view abstract

36. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Author: Martin M; Rodriguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munarriz B; Rodriguez CA; Crespo C; de Alava E; Lopez Garcia-Asenjo JA; Guitian MD; Almenar S; Gonzalez-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Segui MA; Mayordomo JI; Anton A; Baena JM; Plazaola A; Modolell A; Pelegri A; Mel JR; Aranda E; Adrover E; Alvarez JV; Garcia Puche JL; Sanchez-Rovira P; Gonzalez S; Lopez-Vega JM;
Institution: Servicio de Oncologia Medica, Hospital Universitario San Carlos, Ciudad Universitaria s/n, 28040 Madrid, Spain. mmartin@geicam.org
Journal: J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. Epub 2008 May 27.
Abstract URL: Click here to view abstract

37. Neoadjuvant paclitaxel for operable breast cancer: multicenter phase II trial with clinical outcomes.

Author: Kimura M; Sano M; Fujimori M; Nakagomi H; Negishi T; Yanagita Y; Sato N;
Institution: Department of Surgery, General Ota Hospital, Ota, Gunma 373-8585, Japan. kimuraota@yahoo.co.jp
Journal: Anticancer Res. 2008 Mar-Apr;28(2B):1239-44.
Abstract URL: Click here to view abstract

38. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.

Author: Gomez HL; Doval DC; Chavez MA; Ang PC; Aziz Z; Nag S; Ng C; Franco SX; Chow LW; Arbushites MC; Casey MA; Berger MS; Stein SH; Sledge GW;
Institution: Instituto Nacional de Enfermedades Neoplasicas, Hospital Alberto Sabogal, Lima, Peru. hgomez@inen.sld.pe
Journal: J Clin Oncol. 2008 Jun 20;26(18):2999-3005. Epub 2008 May 5.
Abstract URL: Click here to view abstract

39. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

Author: Seidman AD; Berry D; Cirrincione C; Harris L; Muss H; Marcom PK; Gipson G; Burstein H; Lake D; Shapiro CL; Ungaro P; Norton L; Winer E; Hudis C;
Institution: Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. seidmana@mskcc.org
Journal: J Clin Oncol. 2008 Apr 1;26(10):1642-9.
Abstract URL: Click here to view abstract

40. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.

Author: Rivera E; Mejia JA; Arun BK; Adinin RB; Walters RS; Brewster A; Broglio KR; Yin G; Esmaeli B; Hortobagyi GN; Valero V;
Institution: Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Journal: Cancer. 2008 Apr 1;112(7):1455-61.
Abstract URL: Click here to view abstract

41. Interstitial laser thermotherapy (ILT) of breast cancer.

Author: Haraldsdottir KH; Ivarsson K; Gotberg S; Ingvar C; Stenram U; Tranberg KG;
Institution: Department of Surgery, Lund University Hospital, SE-22185 Lund, Sweden.
Journal: Eur J Surg Oncol. 2008 Jul;34(7):739-45. Epub 2008 Mar 4.
Abstract URL: Click here to view abstract

42. Changing indications for surgery in patients with stage IV breast cancer: a current perspective.

Author: Morrogh M; Park A; Norton L; King TA;
Institution: Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Journal: Cancer. 2008 Apr 1;112(7):1445-54.
Abstract URL: Click here to view abstract

43. Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy: a randomized controlled trial.

Author: Courneya KS; McKenzie DC; Mackey JR; Gelmon K; Reid RD; Friedenreich CM; Ladha AB; Proulx C; Vallance JK; Lane K; Yasui Y; Segal RJ;
Institution: Faculty of Physical Education and Recreation, University of Alberta, Edmonton, Alberta, Canada. kerry.courneya@ualberta.ca
Journal: Cancer. 2008 Apr 15;112(8):1845-53.
Abstract URL: Click here to view abstract

44. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

Author: Chia S; Gradishar W; Mauriac L; Bines J; Amant F; Federico M; Fein L; Romieu G; Buzdar A; Robertson JF; Brufsky A; Possinger K; Rennie P; Sapunar F; Lowe E; Piccart M;
Institution: Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, 600 West 10 Avenue, Vancouver, BC, Canada. schia@bccancer.bc.ca
Journal: J Clin Oncol. 2008 Apr 1;26(10):1664-70. Epub 2008 Mar 3.
Abstract URL: Click here to view abstract

45. Long-term follow-up of acupuncture and hormone therapy on hot flushes in women with breast cancer: a prospective, randomized, controlled multicenter trial.

Author: Frisk J; Carlhall S; Kallstrom AC; Lindh-Astrand L; Malmstrom A; Hammar M;
Institution: Division of Obstetrics and Gynaecology, Department of Molecular and Clinical Medicine, Faculty of Health Sciences, University Hospital of Linkoping, Sweden.
Journal: Climacteric. 2008 Apr;11(2):166-74.
Abstract URL: Click here to view abstract

46. A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer.

Author: Fenlon DR; Corner JL; Haviland JS;
Institution: School of Nursing & Midwifery, University of Southampton, Southampton, UK. dfenlon@soton.ac.uk <dfenlon@soton.ac.uk>
Journal: J Pain Symptom Manage. 2008 Apr;35(4):397-405.
Abstract URL: Click here to view abstract

47. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Author: Burstein HJ; Elias AD; Rugo HS; Cobleigh MA; Wolff AC; Eisenberg PD; Lehman M; Adams BJ; Bello CL; DePrimo SE; Baum CM; Miller KD;
Institution: Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA. hburstein@partners.org
Journal: J Clin Oncol. 2008 Apr 10;26(11):1810-6. Epub 2008 Mar 17.
Abstract URL: Click here to view abstract

48. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.

Author: Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE;
Institution: University of Vermont College of Medicine, 1 South Prospect St, Saint Joseph 3400, Burlington, VT 05401, USA. hyman.muss@uvm.edu
Journal: J Clin Oncol. 2008 Apr 20;26(12):1956-64. Epub 2008 Mar 10.
Abstract URL: Click here to view abstract

49. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

Author: Crivellari D; Sun Z; Coates AS; Price KN; Thurlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens RJ; Castiglione-Gertsch M; Gelber RD; Colleoni M; Lang I; Del Mastro L; Gladieff L; Rabaglio M; Smith IE; Chirgwin JH; Goldhirsch A;
Institution: IBCSG Coordinating Center, Effingerstrasse 40, CH-3008 Bern, Switzerland. dcrivellari@cro.it
Journal: J Clin Oncol. 2008 Apr 20;26(12):1972-9. Epub 2008 Mar 10.
Abstract URL: Click here to view abstract

50. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib.

Author: Dirix LY; Ignacio J; Nag S; Bapsy P; Gomez H; Raghunadharao D; Paridaens R; Jones S; Falcon S; Carpentieri M; Abbattista A; Lobelle JP;
Institution: Medical Oncology Unit, Oncologisch Centrum Sint-Augustinus, Oosterveldlaan 24, 2610 Wilrijk, Belgium. luc.dirix@gvagroup.be
Journal: J Clin Oncol. 2008 Mar 10;26(8):1253-9.
Abstract URL: Click here to view abstract

51. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

Author: Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU;
Institution: Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, 1 route du Muids, Genolier, Switzerland. maapro@genolier.net
Journal: J Clin Oncol. 2008 Feb 1;26(4):592-8.
Abstract URL: Click here to view abstract

52. A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer.

Author: Gaui Mde F; Amorim G; Arcuri RA; Pereira G; Moreira D; Djahjah C; Biasoli I; Spector N;
Institution: Oncology and Pathology Services, National Cancer Institute, Rio de Janeiro, Brazil. mfgaui@hotmail.com
Journal: Am J Clin Oncol. 2007 Feb;30(1):78-81.
Abstract URL: Click here to view abstract

53. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.

Author: Toledano A; Azria D; Garaud P; Fourquet A; Serin D; Bosset JF; Miny-Buffet J; Favre A; Le Floch O; Calais G;
Institution: Department of Radiation Oncology, Henry Kaplan, Hopital Bretonneau, Tours, France. alain.toledano@gmail.com
Journal: J Clin Oncol. 2007 Feb 1;25(4):405-10.
Abstract URL: Click here to view abstract

54. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer.

Author: Carpenter JS; Storniolo AM; Johns S; Monahan PO; Azzouz F; Elam JL; Johnson CS; Shelton RC;
Institution: Indiana University, 1111 Middle Drive NU340D, Indianapolis, Indiana 46202, USA. carpentj@iupui.edu
Journal: Oncologist. 2007 Jan;12(1):124-35.
Abstract URL: Click here to view abstract

55. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Author: Smith I; Procter M; Gelber RD; Guillaume S; Feyereislova A; Dowsett M; Goldhirsch A; Untch M; Mariani G; Baselga J; Kaufmann M; Cameron D; Bell R; Bergh J; Coleman R; Wardley A; Harbeck N; Lopez RI; Mallmann P; Gelmon K; Wilcken N; Wist E; Sanchez Rovira P; Piccart-Gebhart MJ;
Institution: Royal Marsden Hospital, London, UK. ian.smith@rmh.nhs.uk
Journal: Lancet. 2007 Jan 6;369(9555):29-36.
Abstract URL: Click here to view abstract

56. Does patient satisfaction with breast reconstruction change over time? Two-year results of the Michigan Breast Reconstruction Outcomes Study.

Author: Alderman AK; Kuhn LE; Lowery JC; Wilkins EG;
Institution: Section of Plastic Surgery, Department of Surgery, The University of Michigan, Medical Center, Ann Arbor, MI 48109-0340, USA.
Journal: J Am Coll Surg. 2007 Jan;204(1):7-12. Epub 2006 Nov 16.
Abstract URL: Click here to view abstract

57. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study.

Author: Loibl S; Schwedler K; von Minckwitz G; Strohmeier R; Mehta K; Kaufmann M;
Institution: Department of Obstetrics and Gynecology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany.
Journal: Ann Oncol. 2007 Jan 17;.
Abstract URL: Click here to view abstract

58. Depression and anxiety in women with breast cancer and their partners.

Author: Badger T; Segrin C; Dorros SM; Meek P; Lopez AM;
Institution: College of Nursing, Department of Communication, The University of Arizona, and Arizona Cancer Center, Arizona Health Science Center, Tucson 85721-0203, USA. Tbadger@nursing.arizona.edu
Journal: Nurs Res. 2007 Jan-Feb;56(1):44-53.
Abstract URL: Click here to view abstract

59. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.

Author: Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J;
Institution: Center for Breast Cancer, Research Institute and Hospital, National Cancer Center, 809 Madu-1-dong, Ilsan-gu, Goyang-si, Gyeonggi-do 410-769, Republic of Korea.
Journal: Breast Cancer Res Treat. 2008 Mar;108(2):241-50. Epub 2007 May 3.
Abstract URL: Click here to view abstract

60. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.

Author: Clemons M; Dranitsaris G; Ooi W; Cole DE;
Institution: Division of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada. mark.clemons@uhn.on.ca
Journal: Breast Cancer Res Treat. 2008 Mar;108(1):79-85. Epub 2007 May 2.
Abstract URL: Click here to view abstract

61. A Phase 2 study of perifosine in advanced or metastatic breast cancer.

Author: Leighl NB; Dent S; Clemons M; Vandenberg TA; Tozer R; Warr DG; Crump RM; Hedley D; Pond GR; Dancey JE; Moore MJ;
Institution: Medical Oncology, Princess Margaret Hospital/University Health Network, Toronto, ON, Canada. Natasha.Leighl@uhn.on.ca
Journal: Breast Cancer Res Treat. 2008 Mar;108(1):87-92. Epub 2007 Apr 26.
Abstract URL: Click here to view abstract

62. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.

Author: Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y;
Institution: Department of Surgery, Kansai Medical University Hirakata Hospital, Hirakata, Osaka 573-1191, Japan. yamamotd@hirakata.kmu.ac.jp
Journal: Cancer Chemother Pharmacol. 2008 Mar;61(3):509-14. Epub 2007 May 22.
Abstract URL: Click here to view abstract

63. Cancer risk among Los Angeles women with cosmetic breast implants.

Author: Deapen DM; Hirsch EM; Brody GS;
Institution: Department of Preventive Medicine, Division of Plastic Surgery, and Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. ddeapen@usc.edu
Journal: Plast Reconstr Surg. 2007 Jun;119(7):1987-92.
Abstract URL: Click here to view abstract

64. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.

Author: Burstein HJ; Keshaviah A; Baron AD; Hart RD; Lambert-Falls R; Marcom PK; Gelman R; Winer EP;
Institution: Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. hburstein@partners.org
Journal: Cancer. 2007 Sep 1;110(5):965-72.
Abstract URL: Click here to view abstract

65. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial.

Author: Del Bianco P; Zavagno G; Burelli P; Scalco G; Barutta L; Carraro P; Pietrarota P; Meneghini G; Morbin T; Tacchetti G; Pecoraro P; Belardinelli V; De Salvo GL;
Institution: Clinical Trials and Biostatistics Unit, Istituto Oncologico Veneto - IRCCS, Via Gattamelata 64, Padova, Italy.
Journal: Eur J Surg Oncol. 2008 May;34(5):508-13. Epub 2007 Jul 5.
Abstract URL: Click here to view abstract

66. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.

Author: Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS;
Institution: Department of Oncology, National Taiwan University Hospital, No 7, Chung-Shan South Rd, Taipei 10016, Taiwan. rlhong@ha.mc.ntu.edu.tw
Journal: Cancer Chemother Pharmacol. 2008 Apr;61(5):847-53. Epub 2007 Jul 4.
Abstract URL: Click here to view abstract

67. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.

Author: Semiglazov VF; Semiglazov VV; Dashyan GA; Ziltsova EK; Ivanov VG; Bozhok AA; Melnikova OA; Paltuev RM; Kletzel A; Berstein LM;
Institution: N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia. ssemiglazov@mail.ru
Journal: Cancer. 2007 Jul 15;110(2):244-54.
Abstract URL: Click here to view abstract

68. Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis.

Author: Amadori D; Nanni O; Volpi A; Casadei Giunchi D; Marangolo M; Livi L; Ravaioli A; Rossi AP; Gambi A; Luzi Fedeli S; Perroni D; Scarpi E; Becciolini A; Silvestrini R;
Institution: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Via Maroncelli 34/36, 47014 Meldola, Italy. segronco@ausl.fo.it
Journal: Breast Cancer Res Treat. 2008 Mar;108(2):259-64. Epub 2007 May 26.
Abstract URL: Click here to view abstract

69. Effects of a combined aerobic and resistance exercise program in breast cancer survivors: a randomized controlled trial.

Author: Milne HM; Wallman KE; Gordon S; Courneya KS;
Institution: School of Human Movement and Exercise Science, The University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia. helenmilne@ekit.com
Journal: Breast Cancer Res Treat. 2008 Mar;108(2):279-88. Epub 2007 May 26.
Abstract URL: Click here to view abstract

70. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients.

Author: Langer I; Guller U; Berclaz G; Koechli OR; Schaer G; Fehr MK; Hess T; Oertli D; Bronz L; Schnarwyler B; Wight E; Uehlinger U; Infanger E; Burger D; Zuber M; Langer I; Guller U; Berclaz G; Koechli OR; Schaer G; Fehr MK; Hess T; Oertli D; Bronz L; Schnarwyler B; Wight E; Uehlinger U; Infanger E; Burger D; Zuber M;
Institution: Department of Surgery, University Hospital Basel, Basel, Switzerland.
Journal: Ann Surg. 2007 Mar;245(3):452-61.
Abstract URL: Click here to view abstract

71. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.

Author: Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W;
Institution: Department of Hematology-Oncology, Penn State University, Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033, USA.
Journal: Cancer. 2007 May 15;109(10):1933-9.
Abstract URL: Click here to view abstract

72. Randomized controlled trial comparing a low-fat diet with a weight-reduction diet in breast cancer-related lymphedema.

Author: Shaw C; Mortimer P; Judd PA; Shaw C; Mortimer P; Judd PA;
Institution: Royal Marsden NHS Foundation Trust, London, UK. clare.shaw@rmh.nhs.uk
Journal: Cancer. 2007 May 15;109(10):1949-56.
Abstract URL: Click here to view abstract

73. Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial.

Author: Mutrie N; Campbell AM; Whyte F; McConnachie A; Emslie C; Lee L; Kearney N; Walker A; Ritchie D;
Institution: Department of Sport, Culture and the Arts, Strathclyde University, Glasgow G13 1PP. nanette.mutrie@strath.ac.uk
Journal: BMJ. 2007 Mar 10;334(7592):517. Epub 2007 Feb 16.
Abstract URL: Click here to view abstract

74. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Author: Coombes RC; Kilburn LS; Snowdon CF; Paridaens R; Coleman RE; Jones SE; Jassem J; Van de Velde CJ; Delozier T; Alvarez I; Del Mastro L; Ortmann O; Diedrich K; Coates AS; Bajetta E; Holmberg SB; Dodwell D; Mickiewicz E; Andersen J; Lonning PE; Cocconi G; Forbes J; Castiglione M; Stuart N; Stewart A; Fallowfield LJ; Bertelli G; Hall E; Bogle RG; Carpentieri M; Colajori E; Subar M; Ireland E; Bliss JM;
Institution: Cancer Research UK Department of Cancer Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Imperial College London, Faculty of Medicine, Hammersmith Hospitals Trust, London W12 0NN, UK.
Journal: Lancet. 2007 Feb 17;369(9561):559-70.
Abstract URL: Click here to view abstract

75. Phase II Study of Neoadjuvant Docetaxel, Vinorelbine, and Trastuzumab Followed by Surgery and Adjuvant Doxorubicin Plus Cyclophosphamide in Women With Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancer.

Author: Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D;
Institution: Carolinas Hematology-Oncology Associates; The Blumenthal Cancer Center, Charlotte, NC; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Magee-Womens Hospital, Pittsburgh, PA; Department of Medicine, Tufts-New England Medical Center, Boston, MA; and Division of Hematology-Oncology, University of Tennessee College of Medicine, Memphis, TN.
Journal: J Clin Oncol. 2007 Feb 12;.
Abstract URL: Click here to view abstract